3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On October 17, 2026, Silgan and its subsidiary Silgan Holdings LLC agreed to form a partnership with A-VL Holdco, LP, an investment vehicle affiliated with funds managed by AIP, LLC, in which Silgan's Metal Containers and Closures Business would be contributed to a new entity, MetalCo. The partnership is also linked to MetalCo's proposed purchase of Trivium Packaging B.V., which the filing describes as subject to a put option and consultation processes. The closing is subject to conditions, including the concurrent Trivium closing, so shareholders will not see a completed transaction until those conditions are met.
A-VL Investor will contribute $1.025 billion in cash to MetalCo for 40% of its Class A voting units; Silgan will receive 60% of those units and a distribution of $2.263 billion, less any New Silgan Debt amount.
Silgan may incur up to $1.0 billion of new debt before the closing, which MetalCo would assume.
MetalCo has a put option to buy 100% of Trivium shares for a cash payment of approximately $327.5 million, plus assumption of approximately $3.1 billion of Trivium debt, exercisable after required consultations with an outside date of nine
The Transaction Agreement can be terminated if closing has not occurred by October 15, 2027.
Shareholders of Texas Ventures Acquisition III Corp approved extending the deadline to complete an initial business combination and liquidate its trust account from October 24, 2026 to July 24, 2027. Holders of 17,699,488 Class A shares, about 78.66% of the IPO shares, redeemed for roughly $187,260,583 from the trust, leaving 4,800,512 Class A shares outstanding.
Extension approved at the October 19, 2026 extraordinary general meeting: 19,248,978 votes for and 1,628,247 against
Redemptions of 17,699,488 Class A shares at approximately $10.58 per share, totaling about $187,260,583 from the Trust Account
4,800,512 Class A ordinary shares remain outstanding after redemptions
Deadline for business combination and trust liquidation moves to July 24, 2027
Innventure's Chief Financial Officer, David Yablunosky, ceased to hold that role on October 19, 2026, and will provide transition services as an independent contractor under a consulting agreement through May 14, 2027 or an earlier termination date. The company said Eric Stober has joined as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, and that Chief Growth Officer Roland Austrup's service will end October 31, 2026, as finance, accounting, investor relations and communications are consolidated under Stober.
Yablunosky ceased to serve as CFO and principal financial and accounting officer on October 19, 2026.
Consulting pay is $5,500 per week for weeks of services, plus COBRA premium reimbursement and approved expense reimbursement.
Yablunosky's unvested equity continues to vest through the termination date, which is no later than May 14, 2027.
Chief Growth Officer Roland Austrup's service ends October 31, 2026.
Chord Energy said CEO Daniel Brown resigned effective October 19, 2026, and named Michael Lou, its former Chief Strategy and Chief Commercial Officer, as President and CEO and a director. In preliminary third-quarter results, the company said volumes exceeded the high end of its August 2026 guidance and adjusted free cash flow was above expectations, but the filing gives no revenue or net income figures and the financial statements are not yet final.
Daniel Brown resigned as President and CEO and as a director effective October 19, 2026, to pursue another professional opportunity, and will receive no severance.
Michael Lou, age 52, was appointed President and CEO effective October 19, 2026, and will not serve on any Board committees for now.
Chord repurchased $205 million of shares in 3Q26 at an average price of $135.74, and another $44.3 million in 4Q26 to date at $142.32.
At September 30, 2026, cash and cash equivalents were $804.7 million and total debt was $1,482.2 million; a non-operated Marcellus divestiture has $550 million in total gross consideration.
Venu Holding Corporation said its President, William Hodgson, will leave the role effective immediately, with his employment ending December 1, 2026, and no successor named. The company also applied a $12.5 million holdback to reduce its $25 million convertible debenture principal and halve the warrant shares tied to it, which the company said reduces debt service and potential dilution.
William Hodgson ceased to serve as President effective October 13, 2026 (agreed date); employment continues until December 1, 2026, with severance expected over a 90-day period
Debenture principal reduced from $25,000,000 to $12,500,000 via holdback applied as of September 30, 2026; each installment cut from $5,000,000 to $2,500,000
Investor Warrants reduced from 1,000,000 to 500,000 shares; Placement Agent Warrants reduced from 200,000 to 100,000 shares
Aramark completed its additional Series B Preferred Stock investment of $5,010,000 on October 15, 2026; first debenture installment of $2,875,000 paid October 14, 2026
Standex International said Samantha L. Stoddard, currently EVP and CFO of JELD-WEN, will become Vice President, CFO and Treasurer on December 1, 2026, replacing interim CFO Ademir Sarcevic, who will remain an executive vice president. Her offer letter sets a $575,000 base salary, a 75% target bonus, and a 175% of salary long-term incentive target, giving shareholders a clear view of the new principal financial officer and her pay terms.
Samantha L. Stoddard, age 43, joins as CFO and Treasurer effective December 1, 2026, reporting to CEO David Dunbar.
Base salary of $575,000; target bonus of 75% of base salary; long-term incentive target of 175% of base salary.
One-time signing bonus of $402,500, plus sign-on equity of $400,000 in restricted stock units and $1,006,250 in premium-priced options.
Ademir Sarcevic, CFO since May 2026 on an interim basis, will remain Executive Vice President and Group President, Electronics.
Tradeweb Markets agreed to acquire Trumid, an electronic credit trading platform, for a purchase price of $1.970 billion, of which $1.888 billion is cash and $82.0 million is equity issued through LLC Units. The deal is targeted to close in the first half of 2027, subject to regulatory and other closing conditions, and Tradeweb expects it to be accretive to adjusted earnings per share within the first full year after closing.
Purchase price of $1.970 billion: $1.888 billion cash, subject to adjustments, and $82.0 million in equity
Targeted closing in the first half of 2027; the agreement can be terminated if closing has not occurred by October 19, 2027, extendable to a maximum of 24 months after signing
Acquiror would pay Trumid a termination fee of $105 million under certain circumstances
Tradeweb expects the deal to be accretive to adjusted EPS within the first full year after closing; a conference call is set for October 20, 2026 at 8:30 a.m. Eastern time
Curanex Pharmaceuticals disclosed two putative securities class actions in New York state court tied to its August 2025 initial public offering. The suits allege material misstatements and omissions in the IPO registration statement and prospectuses, including risks of stock-price manipulation and underwriter due diligence failures; the Company says it intends to defend them vigorously. The cases are at a preliminary stage and seek unspecified damages, so shareholders cannot yet assess the potential financial effect.
Morales action filed July 23, 2026 (Index No. 159271/2026), naming the Company and its underwriters among more than 20 other defendants
Lovett action filed September 14, 2026 (Index No. 655238/2026), also naming the Company's former CFO, directors and independent auditor
Both complaints seek unspecified compensatory damages and rescission or rescissory damages; neither asserts a fraud claim against the Company
Response deadlines: November 15, 2026 for Morales and December 11, 2026 for Lovett
Rocky Mountain Chocolate Factory reported a fiscal second-quarter net loss of $1.3 million, up from $0.7 million a year earlier, on total revenue of $6.7 million, down from $6.8 million. The company also sold its Durango facility for $6.6 million to a company controlled by the family of its interim CEO and took a $2.0 million Alpine Bank term loan secured by substantially all of its assets, while a board committee is exploring strategic alternatives that may include a sale.
Q2 fiscal 2027 (ended August 31, 2026) total revenue was $6.7 million versus $6.8 million a year earlier.
Net loss was $1.3 million, or $(0.14) per share, compared with $0.7 million, or $(0.09) per share.
Gross margin improved to 8.0% from (0.6)%, while total costs and expenses rose to $7.7 million from $7.3 million.
On October 16, 2026, the Durango property was sold to American Heritage Legacies, LLC for $6.6 million, and a $2.0 million Alpine Bank loan maturing October 16, 2028 was funded.
TCGX Acquisition Corp. II, a blank-check SPAC, closed its initial public offering of 10,000,000 Class A ordinary shares at $10.00 per share, raising $100,000,000 in gross proceeds, and placed the full amount in a U.S. trust account. The company will seek a business combination, with a focus on healthcare and healthcare-related industries, and shareholders' redemption rights depend on whether it completes a deal within 24 months.
IPO of 10,000,000 Class A ordinary shares at $10.00 per share, closed October 19, 2026, for $100,000,000 in gross proceeds
Concurrent private placement of 450,000 shares to the sponsor at $10.00 per share, for $4,500,000
$100,000,000 placed in a trust account at Citibank, N.A.; funds are generally held until a business combination or redemption if none is completed within 24 months
Shares to trade on Nasdaq Capital Market under ticker TCXB beginning October 16, 2026; investors receive no warrants
3M entered into an expanded strategic commercial relationship with a subsidiary of Amazon.com, Inc. and issued that subsidiary a seven-year warrant to buy up to 3,162,015 shares of 3M common stock at $164.89 per share. The filing says 85% of the warrant shares vest based on Amazon payments for optical connectivity and other Data Center products, with full vesting once cumulative payments reach $6 billion. For shareholders, the warrant adds potential dilution, though its vesting ties it to future purchases.
Warrant covers up to 3,162,015 shares of 3M common stock over seven years
Exercise price is $164.89 per common share
85% of warrant shares vest with Amazon payments for optical connectivity and other Data Center products; full vesting at $6 billion in cumulative payments
Remaining warrant shares vest subject to event-based milestones not specified in the filing
AES disclosed that the European Commission unconditionally approved its pending merger on October 15, 2026, and the New York Public Service Commission ruled on October 19, 2026 that no further review is required under New York Public Service Law Section 70. Both are conditions to closing, which still depends on other regulatory approvals and customary conditions, and after closing AES would be jointly owned by investment vehicles linked to Global Infrastructure Management and EQT Infrastructure VI.
European Commission unconditionally approved the merger on October 15, 2026.
New York Public Service Commission issued a declaratory ruling on October 19, 2026 that no further review is required under Section 70.
Closing remains subject to certain additional regulatory approvals and other customary conditions.
Merger agreement with Horizon Parent, L.P. was entered into on March 1, 2026.
Vivos Therapeutics closed on October 16, 2026 its acquisition of an 11% fully diluted stake in SOD Sciences and a 50% co-ownership interest in SOD's pseudohypoxia early-warning test, paying with 12,000 shares of newly created Series C Convertible Preferred Stock and no cash. The preferred converts at $0.15 per share into up to 80,000,000 common shares, which could dilute existing holders, and the company expects the deal to raise stockholders' equity by more than $10 million, which it says may restore compliance with a Nasdaq minimum.
Closed October 16, 2026: 3,057,879 SOD common shares (at least 11% fully diluted) plus a 50% interest in the test and related IP, for 12,000 Series C Preferred with a $12,000,000 aggregate stated value; no cash paid.
Series C converts at $0.15 per share into up to 80,000,000 common shares; until stockholder approval, conversions are capped at 6,718,517 shares, against 33,609,393 common shares outstanding before the signing.
Vivos expects stockholders' equity to rise by more than $10 million, citing $10,380,000 of expected additional equity, and believes this restores compliance with Nasdaq's $2.5 million stockholders' equity requirement, subject to Nasdaq revi
Commercial benefits depend on definitive agreements with AHA, which is in bankruptcy proceedings, and Cleveland Clinic Weston, neither of which had been executed as of the filing.
FreightCar America removed 1,285 railcars tied to a tank car retrofit order from its backlog, saying the customer is unlikely to meet its contract obligations. The company cut its full-year 2026 outlook for deliveries, revenue and Adjusted EBITDA, and reported preliminary third-quarter revenue of $75 million to $77 million, down from $160.5 million a year earlier.
Third-quarter 2026 deliveries were 662 units, versus 1,304 in the third quarter of 2025, and preliminary Adjusted EBITDA ranged from $(0.3) million to $0.3 million, versus $17.0 million a year earlier.
Full-year 2026 revenue outlook was cut to $370 million to $410 million from $410 million to $460 million, and Adjusted EBITDA outlook to $15 million to $19 million from $36 million to $44 million.
Backlog as of September 30, 2026 was 2,660 units valued at $284.5 million after the removal.
Full third-quarter results are scheduled for release on November 9, 2026, with a conference call on November 10, 2026.
Home Bancorp reported third-quarter 2026 net income of $10.1 million, or $1.28 per diluted share, down from $11.6 million, or $1.48, in the second quarter. Nonperforming assets rose to $53.7 million from $39.2 million after six loan relationships totaling $19.5 million were placed on nonaccrual status. The company also said CEO John W. Bordelon will retire effective January 8, 2027, with President Darren E. Guidry succeeding him, and declared a $0.32 quarterly dividend.
Net income was $10.1 million, or $1.28 diluted EPS, versus $11.6 million, or $1.48, in Q2 2026.
Net interest margin fell to 4.19% from 4.24%, while net interest income rose $110,000 to $35.9 million.
Nonperforming assets totaled $53.7 million, or 1.49% of total assets, at September 30, 2026, up from $39.2 million at June 30, 2026.
Bordelon retires as CEO effective January 8, 2027, and remains Chairman; Guidry will become CEO and continue as President.
On October 15, 2026, Chefs' Warehouse entered into a $675 million senior secured term loan maturing October 15, 2033, and used the proceeds to repay its prior term loan and redeem its 2.375% convertible notes due 2028. Holders of about $287.2 million of those notes converted into cash and 2,671,056 shares of common stock, which the company issued on October 15, 2026. The filing shows higher secured debt and new share issuance for shareholders to weigh.
New $675 million senior secured term loan matures October 15, 2033, at SOFR plus 2.00% or alternate base rate plus 1.00%.
Prior term loan with a $305 million facility was repaid in full, with about $244.7 million of obligations settled, and terminated.
Holders of about $287.2 million of 2.375% convertible notes due 2028 converted, and 2,671,056 conversion shares were issued on October 15, 2026.
Asset-based loan amendment raised the letter of credit sublimit from $50 million to $75 million.
JELD-WEN said Chief Financial Officer Samantha L. Stoddard will resign effective November 13, 2026, to pursue an opportunity outside the building products industry, and that she was not leaving over any disagreement with the company. Chief Accounting Officer Jeffrey Embt will serve as interim CFO from that date while keeping his current role, and the company will search for a permanent CFO. The company also reaffirmed its full year 2026 guidance, which was first given on August 3, 2026.
Samantha L. Stoddard resigns as EVP and CFO, effective November 13, 2026; she notified the company on October 13, 2026
Jeffrey Embt, VP and Chief Accounting Officer, becomes Interim CFO and principal financial officer effective November 13, 2026
Embt receives $10,000 per month in additional cash compensation and his target incentive rises to 50% of base salary, prorated for time in the role
Full year 2026 guidance reaffirmed: revenue of $3.1 billion to $3.2 billion and Adjusted EBITDA of $120 million to $150 million
Lear Corporation said CFO Jason Cardew will resign effective February 28, 2027, and retire December 31, 2027, with Jared Fedele, currently Vice President of Finance for Seating and E-Systems, taking over as Senior Vice President and Chief Financial Officer on March 1, 2027. The planned succession with a long internal candidate and an advisory period for Cardew gives shareholders a defined transition, though the filing reports no financial results or guidance changes.
Fedele, age 45, joined Lear in July 2003 and becomes CFO effective March 1, 2027
Fedele receives an initial annual base salary of $750,000 and is eligible for the Annual Incentive Plan and LTSIP
Cardew resigns as CFO effective February 28, 2027, then serves as a consultant at $22,000 per month through December 31, 2027
Fedele's severance is two times base salary plus target bonus, plus 24 months of health coverage, if terminated without cause or for good reason
Matrix Service Company (Nasdaq: MTRX) announced that Dominic A. Savarino will become Senior Vice President and Chief Financial Officer effective November 6, 2026, serving as principal financial and principal accounting officer. He previously was CFO of Diamond Offshore Drilling from 2021 to 2024, and the filing sets out his $500,000 base salary and equity package. The filing does not report any financial results, so the change is a leadership transition for shareholders to monitor.
Dominic A. Savarino appointed Senior Vice President and Chief Financial Officer, effective November 6, 2026
Base salary of $500,000; target bonus 75% of base salary, maximum 150%
One-time special equity grant valued at $450,000; annual equity grant of 140% of base salary beginning August 2027
Change of control severance equal to two times base salary plus target bonus; non-change of control severance of 1.5 times base salary
On October 16, 2026, Curis agreed to sell 16,666,680 shares, or pre-funded warrants in place of shares, with accompanying common warrants for up to 16,666,680 shares, at a combined price of $0.51 per share. Gross proceeds are expected to be about $8.5 million before placement agent fees and expenses, with closing expected on or about October 19, 2026. The company also agreed to lower the exercise price of its January and August 2026 warrants to $0.60, and the new share count and warrants would add to the shares outstanding for existing holders.
Offering of 16,666,680 shares or pre-funded warrants, plus common warrants for up to 16,666,680 shares, at a combined $0.51 per share
Gross proceeds expected to be about $8.5 million, before placement agent fees and offering expenses; placement agents to receive a 6.5% cash fee
New common warrants have a $0.60 exercise price, become exercisable six months after issuance, and terminate April 19, 2032
January 2026 and August 2026 warrants to be amended to a reduced exercise price of $0.60; proceeds expected to fund operations through initial CLL data in 5-10 patients in December 2026
Mobix Labs notified Vision Aerial on October 14, 2026, that it was terminating their July 24, 2026 merger agreement because the contractual termination date had passed. The company said delays in due diligence and financial reporting, including audit information, meant the deal was not completed within the planned timeframe, and it described the termination as amicable.
Termination notice delivered October 14, 2026, under Section 8.1(c) of the Merger Agreement dated July 24, 2026
The merger agreement had been disclosed in a Form 8-K filed July 29, 2026
Company cited delays in due diligence and financial reporting, including receipt of accounting information needed for the audit
Company said it remains open to future opportunities with Vision Aerial
Medtronic said on October 15, 2026 that its exchange offer for MiniMed Group shares had settled and the separation was complete. The offer was 5.4 times subscribed, and Medtronic exchanged its remaining 252,813,348 MiniMed shares, ending its ownership stake in MiniMed. The same filing reports shareholder approval of all six AGM proposals and a leadership expansion for Michael Marinaro, with a base salary of $1,000,000 for fiscal 2027.
Exchange offer settled October 15, 2026; Medtronic exchanged all remaining interest, 252,813,348 MiniMed shares, and the offer was 5.4 times subscribed
Michael Marinaro appointed President, Medtronic, effective October 14, 2026, with oversight of Greater China operations; base salary set at $1,000,000 for fiscal 2027
Supplemental fiscal 2027 long-term incentive awards with an aggregate target value of approximately $3.25 million, to be granted November 2, 2026
All twelve director nominees were elected at the October 15, 2026 Annual General Meeting, and all six proposals passed
Integra LifeSciences entered a $1.65 billion amended and restated credit agreement and closed a $450 million private offering of 9.500% senior secured notes due 2033, both on October 19, 2026. The company used the proceeds and new borrowings to repay in full its Existing Credit Agreement, which had a $1.3 billion revolver and a $775 million term loan. The filing shows new debt and higher-cost secured borrowing terms, but it does not report earnings or guidance changes.
Notes: $450 million principal, 9.500% interest, payable semi-annually, maturing November 1, 2033
Credit agreement: $600 million revolver and $600 million term loan A (five-year), plus $450 million term loan B (seven-year)
Term Loan B applicable rate is 4.25%; revolver and term loan A initially 3.00%, adjusting to 2.00% to 3.25% after the December 31, 2026 quarter
Existing $1.3 billion revolver and $775 million term loan were repaid in full with no early termination penalties
Steel Dynamics announced six leadership promotions and role changes in an October 19, 2026 press release filed as Exhibit 99.1. The filing identifies Theresa E. Wagler as incoming President and Chief Executive Officer and Rick Poinsatte as incoming Chief Financial Officer, which signals a change in top executive roles for shareholders to note.
Three Senior Vice Presidents promoted effective October 1, 2026: Chad Bickford, Jeff Hansen and Tommy Scruggs
Daniel Keown named Senior Vice President over three flat rolled steel production facilities, and Yury Krotov named Vice President over four long product steel mills, both effective November 1, 2026
Dominic Freiburger named Vice President and Treasurer, reporting to Rick Poinsatte, incoming CFO
Theresa E. Wagler is described as incoming President and Chief Executive Officer
CRISPR Therapeutics promoted Andrew J. Silver, its SVP of Finance, to Chief Financial Officer effective immediately on October 19, 2026. CFO Raju Prasad resigned the same day to pursue external opportunities and is expected to remain employed until on or before November 30, 2026. The filing says Dr. Prasad's resignation was not due to any disagreement with the company on financial or accounting matters.
Andrew J. Silver, 42, becomes CFO and principal financial and accounting officer effective October 19, 2026; he has been SVP, Finance since January 2025 and joined the company in October 2018.
Silver's employment agreement sets an annual salary of $515,000, a target bonus of 45% of base salary, and a one-time grant of 25,000 restricted stock units vesting on the second anniversary of the grant date.
Raju Prasad, Ph.D. resigned as CFO; he is expected to remain employed until a date on or before November 30, 2026.
Under the agreement, termination without Cause or resignation for Good Reason carries a six-month notice period, extended to 12 months if it occurs within 12 months after a Change in Control.
Torrid Holdings' Chief Financial Officer, Paula Dempsey, resigned on October 14, 2026, effective November 12, 2026, and the company says her departure is amicable and not tied to any disagreement on accounting or reporting. Will Langley, former Belk CFO, was appointed interim CFO effective October 28, 2026, with a $702,000 base salary and a 65% target bonus.
Paula Dempsey resigned as CFO effective November 12, 2026; the company says she is leaving to pursue another opportunity and will serve through mid-November.
Will Langley was appointed interim CFO effective October 28, 2026, after serving as CFO of Belk, Inc. from January 2020 through May 2025.
Langley's pay: $702,000 annual base salary and a target annual bonus of 65% of base, prorated for 2026 and requiring employment through January 30, 2027.
On October 16, 2026, Enerpac Tool Group entered into an Amended and Restated Credit Agreement with PNC Bank as administrative agent, replacing its September 2022 facility that was due to mature in September 2027. The new agreement provides a $550 million revolving credit facility and a $300 million term loan, both maturing October 16, 2031, and initial borrowings were used to repay the existing debt and pay fees.
Revolving credit facility of $550 million, including a $200 million sublimit for Euro, Pound Sterling or other agreed foreign currency borrowings
$300 million term loan with quarterly principal payments of $0.9375 million starting March 1, 2028, rising over time, and the remaining balance due at maturity on October 16, 2031
Initial interest at term SOFR plus 1.125%, with margins adjusted by net leverage ratio; the company may request up to $425 million in additional facility capacity, subject to lender commitments
Scienture Holdings reported preliminary, unaudited revenue of about $1.22 million for the quarter ended September 30, 2026, up 256% from about $344,000 in the second quarter, driven by the August 2026 REZENOPY launch and continued Arbli sales growth. The company also regained compliance with Nasdaq's $1.00 minimum bid price requirement, and Nasdaq closed the matter, so its common stock will remain listed. The filing does not report profit or earnings per share for the quarter.
Preliminary unaudited Q3 2026 revenue of about $1.22 million, versus about $344,000 in Q2 2026 (up 256%).
Arbli wholesale unit sales rose 74% sequentially; REZENOPY launched in August 2026 with initial wholesale shipments.
On October 19, 2026, Nasdaq confirmed the stock closed at or above $1.00 for ten consecutive trading days, and the matter is closed.
AGNC Investment Corp. reported a third-quarter 2026 net loss of $1.17 per common share and a comprehensive loss of $1.28 per share, driven by a $5.0 billion unrealized loss on investment securities. Tangible net book value per share fell 16.9% to $7.13 from $8.58 on June 30, 2026, and the company's economic return on tangible common equity was -12.7% after $0.36 in dividends declared. The results matter to shareholders because book value per share dropped sharply, while the company raised $992 million by issuing 97.6 million common shares.
Net loss of $(1,357) million, or $(1.17) per common share, for the quarter ended September 30, 2026, compared with net income of $654 million in the prior quarter
Tangible net book value per common share fell $1.45, or 16.9%, to $7.13 as of September 30, 2026
Net spread and dollar roll income was $0.37 per common share, down from $0.40 in the prior quarter
Issued 97.6 million common shares through at-the-market offerings for net proceeds of $992 million
EyePoint said its Phase 3 LUCIA trial of DURAVYU in wet AMD did not meet its primary non-inferiority endpoint, and its board approved a plan to reduce operating expenses and focus on diabetic macular edema (DME). The plan cuts the workforce by about 53%, concludes the pivotal wet AMD trials early, and carries about $9 million in employee separation charges, which shareholders would bear as a cost.
The LUCIA wet AMD trial did not meet its primary endpoint of non-inferiority, though it met key secondary endpoints, per the press release.
Approximately 53% of positions are affected, with most of the reduction expected in Q4 2026 and completion in the first half of 2027.
Estimated aggregate employee separation charges are about $9 million, and annualized savings are estimated at about $30 million.
Cash, cash equivalents and short-term investments were about $118 million as of September 30, 2026, a preliminary, unaudited figure; pivotal DME Phase 3 topline data is expected in Q4 2027.
TCGX Acquisition Corp., a special purpose acquisition company, signed a Business Combination Agreement on October 18, 2026 with TriGemX Bio, a company developing elismetrep for migraine. The deal would make TriGemX Bio a publicly traded company on Nasdaq under the ticker TGEM, with closing expected in the first quarter of 2027 subject to shareholder and stockholder approvals. For TCGX shareholders, the outcome depends on redemption requests, which could reduce the cash available to the combined company.
Business Combination Agreement dated October 18, 2026, among TCGX, Merger Sub and TriGemX Bio (formerly Kallyope, Inc.).
Expected gross proceeds of about $246 million before transaction costs, assuming no redemptions, including a $160 million PIPE at $10.00 per share and about $86 million from the TCGX trust account.
Pre-money equity value of TriGemX set at $361 million; post-transaction equity value expected to be about $600 million at closing, assuming no redemptions.
Closing expected in the first quarter of 2027; either party may terminate if the deal is not completed by June 30, 2027, subject to limited exceptions.
SkyAI commenced on October 16, 2026, a cash tender offer to buy up to 95% of each class of its common stock and warrants at $3.00 per share or warrant, with the offer set to expire on October 29, 2026 unless extended. If fully subscribed, the purchase would cost about $201.3 million, paid from cash on hand of about $223.8 million as of October 16, 2026. For shareholders, the offer gives an option to sell for cash at a price the company says is about 0.95 times its net asset value, but it would use most of the company's cash.
Offer expires at one minute after 11:59 p.m. New York City time on October 29, 2026, unless extended or terminated early
Seeks up to 48,311,489 common shares, 4,880,734 cash pre-funded warrants, 9,939,850 cryptocurrency pre-funded warrants and 3,955,293 strategic warrants
Company held about $223.8 million in cash as of October 16, 2026, and has sold all of its SOL; the offer has no financing condition
Each class is conditioned on at least 50% of that class being tendered; the Board approved the offer but makes no recommendation to holders
Veradermics said its Phase 3 Study '304' of VDPHL01, an oral extended-release minoxidil tablet, met all primary and secondary endpoints with high statistical significance in 536 men with mild-to-moderate pattern hair loss. The company reported no treatment-related serious adverse events and no cardiac adverse events of special interest, and it said the results add to positive data from Study '302' for a potential first FDA-approved oral non-hormonal treatment for men, though approval has not been sought or granted.
At Month 6, hair count rose 28.6 hairs/cm² (once daily) and 36.4 hairs/cm² (twice daily) versus 6.6 hairs/cm² for placebo, each with p<0.0001.
55.7% (once daily) and 68.7% (twice daily) of patients reported 'improved' or 'much improved' hair coverage versus 15.0% on placebo.
Hypertrichosis was the only adverse event above 5% with a difference from placebo: 2.2% (once daily) and 9.0% (twice daily) versus 0% on placebo.
Veradermics plans to report Part B of Study '302' later in 2026.
Shareholders approved extending Quartzsea Acquisition Corp's deadline to complete an initial business combination from October 19, 2026 to February 19, 2027, through up to four one-month extensions. Holders of 3,344,937 shares redeemed for an aggregate of about $35.8 million, leaving 3,659,681 public ordinary shares outstanding, and each monthly extension requires a deposit into the trust account.
Shareholders approved all three proposals at the Extraordinary General Meeting held October 13, 2026.
Holders of 3,344,937 ordinary shares redeemed at about $10.71 per share, for about $35.8 million in total.
Each one-month extension requires a deposit of the lesser of $100,000 or $0.033 per outstanding public share.
Following the redemptions, 3,659,681 public ordinary shares remain outstanding.
On October 19, 2026, Data I/O signed a definitive agreement to acquire V-TEK, Inc., a Mankato, MN maker of semiconductor handling and packaging solutions, and A&J Programming, Inc., a San Jose, CA device programming service provider. The total purchase price is about $23 million, paid in cash and Company common stock, and the company said the acquisition is expected to close this week. The same day, it announced a proposed private placement of about $13.25 million that includes convertible debentures and common shares, with a shareholder vote needed for issuances above 19.9% of shares outstanding.
Total purchase price of about $23 million, including about $3 million in Data I/O common stock (about 1.12 million shares)
Proposed private placement of about $13.25 million, with $7.25 million in debentures converting at $2.68 per share
Special shareholder meeting expected within 120 days of closing to approve issuances above 19.9% of shares outstanding
Lead investor from the June 2026 private placement committed an additional $4.0 million
BNB Standard Corporation's Board appointed Alex Odagiu as Chief Executive Officer effective October 19, 2026, and he continues as a director. William B. Miller, who had been Interim Principal Executive Officer, will remain Chief Financial Officer. The filing reports no financial results; for shareholders the change is in top executive leadership and compensation terms.
Odagiu, age 35, has been Interim President and a director since June 2026 and was an Investment Partner at YZiLabs from September 2025 until the Effective Date.
Employment Agreement provides a $525,000 annual base salary and a target annual bonus of 75% of base salary.
New hire RSU grant equal to 2.5% of common shares outstanding, to be granted after stockholder approval of the 2026 Equity Incentive Plan; 60% is performance-based.
Consulting Agreement with W4 LLC, owned by Odagiu, was terminated on the Effective Date; the Company had accrued $70,968 to W4 LLC.
On October 18, 2026, Cardinal Infrastructure Group amended its agreement to acquire Hughes Brothers Construction Inc. The purchase price remains $357.5 million, but consideration shifts to 60% cash and 40% Cardinal Class A common stock, up from 50% of each, and the earnout is revised to a maximum of $162.5 million. For shareholders, the deal adds new shares and debt-funded cash, and the company expects closing in the fourth quarter of 2026.
Purchase price stays at $357.5 million; cash portion is $214.5 million, versus 50% cash under the original terms.
Stock consideration is 5,255,420 shares, based on a $27.21 Signing Date VWAP, with a 180-day lock-up for the sellers.
Earnout of up to $162.5 million depends on Hughes Brothers adjusted EBITDA for the twelve months ending June 30, 2027; the maximum would add up to 2,388,827 shares.
Closing is expected in the fourth quarter of 2026, subject to HSR clearance and other conditions; Cardinal says the deal is immediately accretive to adjusted EBITDA per share.
Eos Energy said preliminary third-quarter 2026 revenue of $82 million to $83 million rose about 169% to 172% from a year earlier, while gross margin remained a loss of 53% to 55%. The company now expects full-year 2026 revenue in the lower half of its $300 million to $350 million range, and the figures are unaudited and may change before full results on November 5, 2026.
Preliminary Q3 2026 revenue of $82 million to $83 million, up about 19% to 21% sequentially and 169% to 172% year over year
GAAP gross margin of (55)% to (53)%, an improvement of about 16 to 18 percentage points versus Q2 2026
Total cash including restricted cash was about $344 million on September 30, 2026, down from $364 million on June 30, 2026; backlog was about $765 million
Full-year 2026 revenue now expected in the lower half of the $300 million to $350 million range; full Q3 results due November 5, 2026
H.B. Fuller's board unanimously rejected a second unsolicited, non-binding proposal from Ancora Holdings Group to buy its Building Adhesive Solutions business for between $1.2 billion and $1.4 billion in cash. The board said the modest price increase did not capture the business's value and that the offer's terms were highly conditional. The company will run a market check of select market segments and product lines, with proceeds intended for deleveraging, and expects to complete it by year end 2026.
Ancora's second non-binding proposal priced the Building Adhesive Solutions business at $1.2 billion to $1.4 billion in cash
Board unanimously rejected the proposal, citing value and highly conditional terms
Market check covers segments and product lines less integral to the portfolio, with completion expected by year end 2026
MKS Inc. has agreed to sell its Ophir Optics business to TTM Technologies for $650 million in cash, subject to customary closing adjustments. The company says the proceeds will help strengthen its balance sheet, and the deal is expected to close in the second quarter of 2027, subject to regulatory approvals and governmental consents.
Purchase price is $650 million in cash, subject to customary closing adjustments
The price is an estimated multiple of over 18x projected FY 2026 Adjusted EBITDA for Ophir Optics
Excludes the Ophir Instruments laser characterization business and the Ophir brand
Expected to close in the second quarter of 2027; J.P. Morgan is exclusive financial advisor
On October 16, 2026, Teamshares Continuity Holdings LLC, a subsidiary of Teamshares Inc, entered into a $130.0 million senior secured term loan and used it, with cash on hand, to repay in full the $150.0 million Existing Credit Agreement, with a payoff of about $152.8 million including accrued interest. The new loan carries a rate of one-month Term SOFR (3.00% floor) plus 9.50%, down from 11.00% on the old facility, but while it is outstanding the Company may not pay dividends or repurchase its equity without the agent's consent.
New $130.0 million term loan matures on the fourth anniversary of the October 16, 2026 closing date, with quarterly principal payments starting December 31, 2026
Interest rate is one-month Term SOFR (3.00% floor) plus 9.50%, versus Term SOFR (3.00% floor) plus 11.00% on the repaid facility
Company expects annual interest expense to decrease by approximately $5 million at current SOFR levels, per the press release
Credit agreement restricts dividends and equity repurchases without Agent consent, limiting shareholder payouts while the loan is outstanding
TTM Technologies agreed to acquire the Ophir Optics business from MKS Inc. for approximately $650 million in an all-cash deal, subject to customary closing adjustments. The company expects the deal to close in the second quarter of 2027, subject to regulatory approvals, and expects it to be immediately accretive to its Adjusted EBITDA Margin and Non-GAAP Diluted EPS.
Purchase price is approximately $650 million, all cash, with funding from cash on hand, future cash flow and its existing revolving credit facility.
The transaction multiple is estimated at roughly 10.3x expected FY 2027 Adjusted EBITDA of Ophir Optics, without synergies.
Expected close is the second quarter of 2027, subject to regulatory approvals and governmental consents and permits.
Excludes MKS's Ophir Instruments laser characterization business and the Ophir brand.
Expand Energy's board appointed Daniel E. Brown, formerly CEO of Chord Energy, as President and Chief Executive Officer, effective when his employment begins, expected October 26, 2026. Michael Wichterich, who has been interim CEO, will step down from that role and remain Chairman of the Board, and Brown will also join the board. The filing sets out a $1,000,000 base salary and a $8,750,000 annual long-term incentive target, plus a make-whole equity award for compensation forfeited at his prior employer.
Effective date: employment anticipated to begin October 26, 2026; Brown also joins the board as an employee director
Base salary $1,000,000 with a 125% annual cash bonus target; annual long-term incentive target value $8,750,000
Make-whole award: RSUs with a target value of $4,726,662 and PSUs with a target value of $10,925,584
Michael Wichterich ceases as interim CEO but continues as Chairman; he keeps a pro-rata 2026 long-term incentive award
Mattel appointed Peter Griffith, formerly CFO of Amgen, as Chief Financial Officer effective October 20, 2026, and as a non-independent board director. Paul Ruh, the current CFO, moves to an advisory role through December 31, 2026, and director Adriana Cisneros resigned from the board on October 18, 2026. The filing does not report financial results, so it does not change reported figures, but it marks a change in the company's top finance role.
Peter Griffith starts as CFO on October 20, 2026; he reports to Chairman and CEO Roger Lynch.
Griffith's offer includes a $1,300,000 base salary, a target bonus of 100% of salary, and a $3,300,000 performance-based RSU award.
Paul Ruh's separation agreement keeps his $950,000 base salary through December 31, 2026, when his employment ends.
Adriana Cisneros resigned from the board on October 18, 2026, and the filing says the resignation was not due to a disagreement with the company.
Silence Therapeutics agreed on October 18, 2026 to be acquired by Merck KGaA, Darmstadt, Germany in an all-cash deal valued at about $1.3 billion in equity value. Shareholders and ADS holders would receive $20.00 in cash per American Depositary Share, a 130% premium to the October 16, 2026 closing ADS price, and the transaction was unanimously approved by the Silence board.
Consideration of $20.00 in cash per ADS, with each ADS representing three ordinary shares ($6.6667 per share)
Equity value of approximately $1.3 billion and enterprise value of $1.1 billion; 82% premium to the 30-day volume-weighted average price of $10.99
Expected close in the first quarter of 2027, subject to shareholder approval, High Court sanction and regulatory approvals; End Date of April 30, 2027
Silence must pay Merck KGaA a $13 million termination fee in certain circumstances; securityholders with about 14% of voting power signed voting and support agreements
Dynex Capital reported a third-quarter 2026 net loss of $(1.34) per common share, compared with net income of $0.80 per share in the prior quarter. Book value per common share fell $1.99 to $10.91, which the company attributed mainly to wider Agency MBS spreads, and total economic return was $(1.48) per share, while $0.51 per share in dividends was declared.
Net loss per common share of $(1.34), versus net income of $0.80 per share in the prior quarter
Book value per common share of $10.91 as of September 30, 2026, down from $12.90 on June 30, 2026
Dividends declared of $0.51 per common share; total economic return of $(1.48) per share, or (11.5)% of beginning book value
Raised $384 million of capital, including $268 million of common equity through the ATM program and $116 million of 9.375% Series D preferred stock; leverage rose to 9.0 times shareholders' equity from 8.1 times
Centrus Energy Corp. bought 100% of Westerman Holdings, LLC on October 16, 2026, from the trustee of the Westerman Employee Stock Ownership Trust for approximately $116.0 million. Westerman already makes centrifuge casings and other major components for Centrus, and the company says the deal secures that supply chain and diversifies its revenue into non-nuclear markets. Centrus expects the acquisition to be accretive to adjusted earnings per share in the first year after closing, and it issued $21.0 million of Class A common stock as part of the price.
Purchase price of approximately $116.0 million, including $95.0 million in cash and $21.0 million in Class A common stock, closed October 16, 2026.
About $31.5 million went to Westerman subordinated noteholders and $12.7 million to its term loan lender, paid out of the purchase price.
Centrus expects the deal to be accretive to adjusted EPS in the first year after closing; the price is subject to a customary working capital adjustment.
Westerman has about 400 employees and four facilities in Ohio, Oklahoma and Wyoming, and Centrus plans to file a shelf registration for the stock issued.
Silgan Holdings said it will combine its Metal Containers and Food and Beverage Flat Cap Closures businesses with Trivium Packaging in a partnership with funds affiliated with American Industrial Partners (AIP), with the partnership acquiring Trivium in an all-cash deal at a $3.4 billion enterprise value. Silgan expects about $2.3 billion of cash proceeds and a 60% stake in the new partnership, and it expects the deal to be at least 15% accretive to adjusted EPS and free cash flow, including $225 million of expected synergies. The deal is expected to close in mid-2027, subject to regulatory approvals and other conditions, and Silgan confirmed its third-quarter and full-year 2026 adjusted EPS outlook.
Silgan MCC will combine Silgan's Metal Containers and Flat Cap Closures businesses with Trivium at a $3.4 billion enterprise value for Trivium, or 7.1x LTM Adjusted EBITDA
Silgan receives approximately $2.3 billion of cash proceeds and retains 60% ownership; AIP holds 40% and contributes approximately $1.0 billion of cash equity
Expected synergies of $225 million by year three, with about $75 million in year one and $150 million in year two; Silgan expects at least 15% adjusted EPS accretion
Expected close in mid-2027; Silgan MCC net leverage estimated at about 4.0x pro forma
EquipmentShare raised its full-year 2026 financial guidance for a second time, citing strong customer demand, disciplined execution and rising productivity across its rental network. The higher outlook covers total revenue and Adjusted Core EBITDA, and the company says the increase reflects growth in its rental operations, though it has not yet reported actual results for the quarter ended September 30, 2026.
Total revenue guidance is now $5,808 million to $6,045 million, up from $5,254 million to $5,682 million under prior guidance dated July 9, 2026.
Adjusted Core EBITDA guidance is now $2,136 million to $2,224 million, up from $1,946 million to $2,058 million.
The midpoint full-year growth outlook for the Equipment Rental and Services Operations segment revenue increased to 43% from 33%.
Actual results for the quarter ended September 30, 2026 will be provided at the third quarter earnings call.
Disc Medicine reported topline results from the pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP), saying the trial met all primary and secondary endpoints. The company plans to resubmit a New Drug Application to the FDA by the end of 2026, with an FDA decision anticipated by mid-2027, so the results bear directly on the timing of a possible approval for its lead program.
Both co-primary endpoints were statistically significant: whole-blood PPIX fell 41.4% vs. placebo (p<0.0001), and time in light without pain rose 12.2 hours vs. placebo (p=0.0010)
Phototoxic reactions fell in incidence (p<0.0001 vs. placebo), and dizziness was the most common adverse event in the bitopertin group at 50%
The trial enrolled 183 patients, and the company plans an NDA resubmission by end of 2026 with an FDA decision anticipated by mid-2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.